Stay updated with breaking news from Ancer Immunotherapy. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Researchers at Wake Forest School of Medicine have discovered that a nanoparticle therapeutic enhances cancer immunotherapy and is a possible new approach in treating malignant pleural effusion (MPE).
Bristol Myers Squibb is paying $150 million up front for global rights to an Immatics biologic drug designed to recruit a patient’s T cells to go after cancer cells. It’s the latest deal in the field of cancer drug developers aiming for off-the-shelf treatments intended to be easier and less expensive to manufacture, distribute, and administer compared to earlier cell therapies.
Johns Hopkins astrophysicist, Alexander Szalay, Ph.D., and Kimmel Cancer Center pathologist Janis Taube, M.D., M.Sc., received a Life Sciences 2021 award for AstroPath at this year's Falling Walls Science Summit, an international event honoring research breakthroughs from across the globe.
In recent years, tumor immunotherapy has emerged as a highly promising and much-touted oncological approach.
Adicet Bio makes its therapies from gamma delta T cells, a rare type of immune cell that the company believes offer advantages compared to other cell therapies. The company now has early Phase 1 data that bring some validation to the approach.